Cubital Tunnel Syndrome Market Research Report – Global Forecast till 2023

Cubital Tunnel Syndrome Market Research Report – Global Forecast till 2023

ID: MRFR/HC/3210-HCRR | November, 2017 | Region: Global | 110 pages | Half-Cooked Research Reports

Cubital Tunnel Syndrome Market Research Report: By Cause (Injury, Noncancerous Fatty Tumor, Bone Tumor, Inflammation), Treatment (Diagnosis (MRI, X-Ray), Therapy (Non-Operative, Operative)), End User (Hospital, Retail Pharmacy) - Global Forecast Till 2023 



Market Scenario:


Cubital tunnel syndrome is a condition of increased pressure on the ulnar nerve in the elbow. The ulnar nerve controls muscles and feeling in the hand. Furthermore, it can be caused by direct pressure, stretching, or decreased blood flow to the ulnar nerve. According to the WHO (2014), the incidence of carpal tunnel syndrome is >3 new cases per 1000 persons every year. Women are 3-4 times more susceptible than men. Increasing prevalence of the cubital tunnel syndrome is the major driving factor for the growth of the market. Moreover, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, geriatric population is more likely to suffer from this disease; According to the Aging World in 2015, 562 million (or 8.0 %) were aged 65 and over across the globe, this has increased the prevalence of the diseases and contributed to the growth of the market. However, lack of awareness among people and high cost of surgeries may restrain the growth of the market.


The global cubital tunnel syndrome market is expected to grow at a CAGR of 5.6% during forecast period 2017-2023. 



Intended Audience



  • Biotechnological institutes

  • Pharmaceutical companies

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories 



Figure 1:- Global cubital tunnel syndrome
market share, by region (%)

cubital tunnel syndrome market


Sources: WHO, annual reports, press release, white paper, and company presentation


 


Segmentation


The global cubital tunnel syndrome market is segmented on the basis of causes, treatment, and end users.


On the basis of causes, the market is segmented into injury, noncancerous fatty tumors, bone tumors, inflammation, and others.


On the basis of treatment, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into nerve compression tests, X-ray, electrodiagnostic studies, MRI, and others. The therapy is further segmented into non-operative, and operative. The non-operative is further classified into NSAIDs and steroids.
On the basis of end users, the market is segmented into hospital, retail pharmacy, and other. 



Regional Analysis


The Americas dominates the global cubital tunnel syndrome market owing to large patient population. Additionally, increasing geriatric population, changing lifestyle, and increasing healthcare expenditure have boosted the growth of the market in America. According to the Population Reference Bureau, the number of Americans ages 65 and over is projected to be more than double from 46 million in 2016 to over 98 million by 2060. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.


Europe is the second largest cubital tunnel syndrome market, which is followed by Asia Pacific. Huge geriatric population, availability of funds for research, and government support for research & development projected to drive the market in Europe.


Asia Pacific is the fastest growing region in the global market due to the presence of a increasing patient population, continuously developing economies, and increasing need for the better treatment. According to the WHO report published in 2015, Asia's elderly population is projected to reach nearly 923 million by 2050.


Whereas, the Middle East & Africa owns the least share of  the global cubital tunnel syndrome market due to the presence of poor economy, especially, in Africa region. The market of this region is dominated by the Middle East due to well-developed healthcare sector and huge healthcare expenditure.


 


Research Methodology



Cubital Tunnel Syndrome Market-


Sources: WHO, annual reports, press release, white paper, and company presentation


 


Key players in global cubital tunnel syndrome market


The major key players in the global cubital tunnel syndrome market: Eli Lily and Company (US), GlaxoSmithKline PLC (UK), Pfizer Inc., Depomed Inc., Novartis International AG (Switzerland), Johnson & Johnson Services Inc. (US), Bristol-Myers Squibb and Company (US),  Sanofi S.A. (France), Debiopharm Group (Switzerland), Baxter Healthcare Corporation (US), Biogen Idec Inc. (US), Amneal Pharmaceuticals LLC. (US), Amgen, Inc. (US)


 

TABLE OF CONTENT    

Chapter 1.    Report Prologue    

Chapter 2.    Market Introduction  
 

      2.1    Definition    

      2.2    Scope of the Study    

            2.2.1    Research Objective    

            2.2.2    Assumptions    

            2.2.3    Limitations    

Chapter 3.    Research Methodology

      3.1    Introduction

      3.2    Primary Research    

      3.3    Secondary research    

      3.4    Market Size Estimation

Chapter 4.    Market Dynamics

      4.1    Drivers    

      4.2    Restrains

      4.3    Opportunities    

      4.4    Challenges

      4.5    Macroeconomic Indicators

      4.6    Technology Trends & Assessment            

Chapter 5.    Market Factor Analysis

      5.1    Porters Five Forces Analysis

            5.1.1    Bargaining Power of Suppliers    

            5.1.2    Bargaining Power of Buyers

            5.1.3    Threat of New Entrants    

            5.1.4    Threat of Substitutes    

            5.1.5    Intensity of Rivalry    

      5.2    Value Chain Analysis

      5.3    Investment Feasibility Analysis    

      5.4    Pricing Analysis

Chapter 6.    Global Cubital Tunnel Syndrome Market, by Causes

     6.1    Introduction

      6.2    Injury

Market Estimates & Forecast, 2017 – 2023

      6.3    Noncancerous Fatty Tumors

Market Estimates & Forecast, 2017 – 2023

      6.4    Bone Tumors

Market Estimates & Forecast, 2017 – 2023

      6.5    Inflammation

Market Estimates & Forecast, 2017 – 2023

Chapter 7.    Global Cubital Tunnel Syndrome Market, by Treatment

    7.1    Introduction

      7.2    Diagnosis 

Market Estimates & Forecast, 2017 – 2023

            7.2.1     Nerve Compression Tests

            7.2.2    X-Ray

            7.2.3    Electrodiagnostic Studies

            7.2.4    MRI

            7.2.5    Others

      7.3    Therapy

Market Estimates & Forecast, 2017 – 2023

            7.3.1    Nonoperative

                7.3.1.1    NSAIDs 

                7.3.1.2    Steroids

            7.3.2    Operative

Chapter 8    Global Cubital Tunnel Syndrome Market, by End User

      8.1    Introduction

      8.2    Hospitals

Market Estimates & Forecast, 2017 – 2023

      8.3    Retail Pharmacy 

Market Estimates & Forecast, 2017 – 2023

      8.4    Others

Chapter 9.    Global Cubital Tunnel Syndrome Market, by Region

      9.1    Introduction

      9.2    America

            9.2.1    North America

                9.2.1.1    US

                9.2.1.1    Canada

            9.2.2    South America

      9.3    Europe

            9.3.1    Western Europe

                9.3.1.1    Germany

                9.3.1.2    France

                9.3.1.3    Italy

                9.3.1.4    Spain

                9.3.1.5    UK

                9.3.1.6    Rest of Western Europe

            9.3.2    Eastern Europe

      9.4    Asia Pacific

            9.4.1    Japan

            9.4.2    China

            9.4.3    India

            9.4.4    Australia

            9.4.5    Republic of Korea

            9.4.6    Rest of Asia Pacific

      9.5    The Middle East & Africa

            9.5.1    United Arab Emirates

            9.5.2     Saudi Arabia

            9.5.3    Oman

            9.5.4    Kuwait

            9.5.5    Qatar

            9.5.6    Rest of the Middle East & Africa

Chapter 10    Company Landscape    

      10.1    Introduction    

      10.2    Market Share Analysis    

      10.3    Key Development & Strategies    

            10.3.1    Key Developments    

Chapter 11    Company Profiles    

      11.1    Novartis AG    

            11.1.1    Company Overview    

            11.1.2    Product Overview    

            11.1.3    Financials    

            11.1.4    SWOT Analysis    

      11.2    Eli Lily and Company     

            11.2.1    Company Overview    

            11.2.2    Product Overview    

            11.2.3    Financial Overview    

            11.2.4    Key Developments    

            11.2.5    SWOT Analysis    

      11.3    GlaxoSmithKline PLC    

            11.3.1    Company Overview    

            11.3.2    Product Overview    

            11.3.3    Financial Overview

            11.3.4    Key Development    

            11.3.5    SWOT Analysis    

      11.4    Pfizer Inc.

            11.4.1    Company Overview    

            11.4.2    Product/Business Segment Overview    

            11.4.3    Financial Overview    

            11.4.4    Key Development    

            11.4.5    SWOT Analysis    

      11.5    Sanofi S.A. 

            11.5.1    Company Overview    

            11.5.2    Product Overview    

            11.5.3    Financial overview    

            11.5.4    Key Developments    

      11.6    Johnson & Johnson Services Inc.     

            11.6.1    Company Overview    

            11.6.2    Product Overview    

            11.6.3    Financial Overview    

            11.6.4    Key Developments    

      11.7    Bristol-Myers Squibb and Company  

            11.7.1    Overview    

            11.7.2    Product Overview    

            11.7.3    Financials    

            11.7.4    Key Developments    

            11.7.5    SWOT Analysis    

    11.8    Others

Chapter 12    MRFR Conclusion    

      12.1    Key Findings    

            12.1.1    From CEO’s View Point    

            12.1.2    Unmet Needs of the Market    

      12.2    Key Companies to Watch    

      12.3    Prediction of Pharmaceutical industry

Chapter 13    Appendix



LIST OF TABLES

Table 1        Cubital Tunnel Syndrome Industry Synopsis, 2017 – 2023

Table 2        Global Cubital Tunnel Syndrome Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3        Global Cubital Tunnel Syndrome Market by Region, 2017 – 2023, (USD Million)

Table 4        Global Cubital Tunnel Syndrome Market by Causes, 2017 – 2023, (USD Million)

Table 5        Global Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 6        Global Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 7        North America Cubital Tunnel Syndrome Market by Causes, 2017 – 2023, (USD Million)

Table 8        North America Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 9        North America Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 10    US Market by Causes, 2017 – 2023, (USD Million)

Table 11    US Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 12    US Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 13    Canada Market by Causes, 2017 – 2023, (USD Million)

Table 14    Canada Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 15    Canada Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 16    South America Market by Causes, 2017 – 2023, (USD Million)

Table 17    South America Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 18    South America Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 19    Europe Market by Causes, 2017 – 2023, (USD Million)

Table 20    Europe Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 21    Europe Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 22    Western Europe Market by Causes, 2017 – 2023, (USD Million)

Table 23    Western Europe Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 24    Western Europe Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 25    Eastern Europe Market by Causes, 2017 – 2023, (USD Million)

Table 26    Eastern Europe Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 27    Eastern Europe Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 28    Asia Pacific Market by Causes, 2017 – 2023, (USD Million)

Table 29    Asia Pacific Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 30    Asia Pacific Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

Table 31    Middle East & Africa Market by Causes, 2017 – 2023, (USD Million)

Table 32    Middle East & Africa Cubital Tunnel Syndrome Market by Treatment, 2017 – 2023, (USD Million)

Table 33    Middle East & Africa Cubital Tunnel Syndrome Market by End Users, 2017 – 2023, (USD Million)

    



LIST OF FIGURES

Figure 1    Research Process

Figure 2    Segmentation for Global Cubital Tunnel Syndrome Market

Figure 3    Segmentation Market Dynamics for Global Cubital Tunnel Syndrome Market

Figure 4    Global Cubital Tunnel Syndrome market Share, by Causes 2016

Figure 5    Global Cubital Tunnel Syndrome market Share, by Treatment 2016

Figure 6    Global Cubital Tunnel Syndrome Market Share, by End Users, 2016

Figure 7    Global Cubital Tunnel Syndrome Market Share, by Region, 2016

Figure 8    North America Cubital Tunnel Syndrome Market Share, by Country, 2016

Figure 9    Europe Cubital Tunnel Syndrome Market Share, by Country, 2016

Figure 10    Asia Pacific Cubital Tunnel Syndrome Market Share, by Country, 2016

Figure 11    Middle East & Africa Cubital Tunnel Syndrome Market Share, by Country, 2016

Figure 12    Global Cubital Tunnel Syndrome Market: Company Share Analysis, 2016 (%)

Figure 13    Novartis AG: Key Financials

Figure 14    Novartis AG: Segmental Revenue

Figure 15    Novartis AG: Geographical Revenue

Figure 16    Eli Lily and Company: Key Financials

Figure 17    Eli Lily and Company: Segmental Revenue

Figure 18    Eli Lily and Company: Geographical Revenue 

Figure 19    GlaxoSmithKline PLC: Key Financials

Figure 20    GlaxoSmithKline PLC: Segmental Revenue

Figure 21    GlaxoSmithKline PLC: Geographical Revenue

Figure 22    Pfizer Inc.: Key Financials

Figure 23    Pfizer Inc.: Segmental Revenue

Figure 24    Pfizer Inc.: Geographical Revenue

Figure 25    Sanof: Key Financials

Figure 26    Sanofi S.A.: Segmental Revenue

Figure 27    Sanofi S.A.: Geographical Revenue

Figure 28    Johnson & Johnson Services Inc.: Key Financials

Figure 29    Johnson & Johnson Services Inc.: Segmental Revenue

Figure 30    Johnson & Johnson Services Inc.: Geographical Revenue

Figure 31    Bristol-Myers Squibb and Company: Key Financials

Figure 32    Bristol-Myers Squibb and Company: Segmental Revenue

Figure 33    Bristol-Myers Squibb and Company: Geographical Revenue